Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 9:34 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 627 matching trials from the live ClinicalTrials.gov search.
Conditions
Cirrhosis, Liver
Interventions
Epigallocatechin gallate (EGCG), Placebo
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Hepatocellular Carcinoma
Interventions
CF102, Placebo
Drug
Lead sponsor
Can-Fite BioPharma
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
2
States / cities
Aurora, Colorado • Dallas, Texas
Completed Not applicable Interventional Results available

Hepatocellular Carcinoma Surveillance in Cirrhotics

NCT04248816
Conditions
Hepatocellular Carcinoma, Cirrhosis
Interventions
Usual care, Opt-out, Opt-out + Incentive
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
615 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Not applicable Interventional Results available

Cirrhosis Medical Home

NCT04581369
Conditions
Cirrhosis, Liver
Interventions
Care Coordinator Intervention for Direct Intervention Group, Care Coordinator Intervention for Standard of Care Group, Caregiver Intervention
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Non-alcoholic Steatohepatitis, Hepatic Impairment, Cirrhosis
Interventions
TVB-2640 - 50 mg
Drug
Lead sponsor
Sagimet Biosciences Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
2
States / cities
Orlando, Florida • San Antonio, Texas
Conditions
Primary Biliary Cholangitis
Interventions
EDP-305 1 mg, EDP-305 2.5 mg, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
40
States / cities
Dothan, Alabama • Little Rock, Arkansas • Coronado, California + 28 more
Conditions
Alcohol-related Liver Disease, Liver Diseases
Interventions
ENGAGE-ALD Application (APP), Treatment Facilitation bundle, Enhanced Usual Care
Behavioral
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Chronic Liver Disease, Cirrhosis, Liver
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Cirrhosis, Hepatitis B, Hepatitis C
Interventions
FibroScan
Device
Lead sponsor
Afdhal, Nezam, M.D.
Individual
Eligibility
18 Years to 90 Years
Enrollment
907 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
Boston, Massachusetts • St Louis, Missouri • Durham, North Carolina
Conditions
Chronic Liver Disease, HepatoCellular Carcinoma, Liver Fibrosis
Interventions
Multispectral CT of the liver
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Not applicable Interventional Accepts healthy volunteers Results available

Ultrasound Based Acoustic Radiation Force Impulse Imaging

NCT01781208
Conditions
Liver Fibrosis, Liver Inflammation
Interventions
Ultrasound-Based Acoustic Radiation Force Impulse (ARFI)
Device
Lead sponsor
University of Michigan
Other
Eligibility
Up to 18 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Completed Phase 2 Interventional Results available

The Effect of Sorafenib on Portal Pressure

NCT01714609
Conditions
Clinically Significant Portal Hypertension
Interventions
Placebo, Sorafenib
Drug
Lead sponsor
Yale University
Other
Eligibility
20 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
6
States / cities
New Haven, Connecticut • West Haven, Connecticut • Boston, Massachusetts + 3 more
Completed No phase listed Observational Accepts healthy volunteers

Technical Validation of MR Biomarkers of Obesity-Associated NAFLD

NCT03674528
Conditions
Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis
Interventions
Magnetic Resonance Elastography (MRE), Liver biopsy
Other · Diagnostic Test
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
2
States / cities
La Jolla, California • Madison, Wisconsin
Conditions
Adult Liver Carcinoma, Liver Cirrhosis
Interventions
18F-Fluoromisonidazole, Arterial Embolization, Computed Tomography, Positron Emission Tomography
Drug · Procedure · Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
19 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Advanced Chronic Liver Disease, Healthy Participants
Interventions
AZD2389, Quinidine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Brooklyn, Maryland
Conditions
Metabolic Associated Fatty Liver Disease, Metabolic Associated Steatotic Liver Disease, Cirrhosis, Liver, NASH, Liver Fibrosis, Liver Fat, Liver Steatoses, Liver Inflammation
Interventions
Not listed
Lead sponsor
Foundation for the National Institutes of Health
Other
Eligibility
18 Years to 75 Years
Enrollment
400 participants
Timeline
2025 – 2027
U.S. locations
4
States / cities
Miami, Florida • Columbus, Ohio • Bellaire, Texas + 1 more
Conditions
Obesity, Liver Diseases, Liver Fibrosis, Liver Fat, Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis, MASLD, MASH, Weight Loss, Insulin Resistance, Insulin Sensitivity, Insulin Sensitivity/Resistance, Metabolic Disease, Diabetes, Diabetes Mellitus, Type 2, NASH With Fibrosis, Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver, Non-alcoholic Steatohepatitis
Interventions
ESG + lifestyle modification, Lifestyle modification
Device · Behavioral
Lead sponsor
Pichamol Jirapinyo, MD, MPH
Other
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts • Morgantown, West Virginia
Conditions
Primary Biliary Cholangitis
Interventions
Seladelpar, PTM Seladelpar, Cilofexor Dose B, PTM Cilofexor Dose A, PTM Cilofexor Dose B, Cilofexor Dose A
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
4
States / cities
Colorado Springs, Colorado • Lakewood Rch, Florida • Atlanta, Georgia + 1 more
Conditions
Cirrhotic Cardiomyopathy
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Nashville, Tennessee • Dallas, Texas
Conditions
Liver Disease Chronic, End Stage Liver DIsease, Cirrhosis, Cirrhosis, Liver, Advanced Cirrhosis
Interventions
LiverPAL
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Active, not recruiting Phase 4 Interventional

Angiotensin 2 for AKI After OLT

NCT04592744
Conditions
Cirrhosis, Liver, End Stage Liver DIsease, Acute Kidney Injury, Liver Transplant; Complications
Interventions
Angiotensin II, Norepinephrine
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Cirrhosis, Spontaneous Bacterial Peritonitis
Interventions
doxycycline
Drug
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older · Female only
Enrollment
841 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Primary Biliary Cholangitis
Interventions
Saroglitazar magnesium 1 mg, Placebo
Drug
Lead sponsor
Zydus Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
3
States / cities
Marietta, Georgia • Indianapolis, Indiana • Houston, Texas
Conditions
Hepatocellular Carcinoma, Cirrhosis, Liver
Interventions
Tremelimumab, Durvalumab
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Antonio, Texas